Article
作者: Koh, Cai Ping ; Ong, Kelly Ooi Kee ; Chng, Wee Joo ; Takizawa, Hitoshi ; Ng, King Pan ; Kham, Shirley Kow Yin ; Yanagida, Masatoshi ; Bahirvani, Avinash Govind ; Asou, Norio ; Iwasaki, Masayuki ; Ding, Ling-Wen ; Yokomizo, Tomomasa ; Shimizu, Ritsuko ; Lau, Jie-Ying Amelia ; Niibori-Nambu, Akiko ; Koeffler, H Phillip ; Tan, Tuan Zea ; Chin, Desmond Wai Loon ; Tenen, Daniel G ; Osato, Motomi ; Yamashita, Namiko ; Mori, Seiichi ; Wang, Chelsia Qiuxia ; Sun, Qiao-Yang ; Yamamoto, Masayuki ; Yang, Henry ; Yeoh, Allen Eng-Juh ; Jacob, Bindya ; Mok, Michelle Meng Huang ; Ito, Yoshiaki ; Du, Linsen ; Matsumura, Takayoshi ; Minami, Takashi ; Suda, Toshio
The genetic lesions that drive acute megakaryoblastic leukemia (AMKL) have not been fully elucidated. To search for genetic alterations in AMKL, we performed targeted deep sequencing in 34 AMKL patient samples and 8 AMKL cell lines and detected frequent genetic mutations in the NOTCH pathway in addition to previously reported alterations in GATA-1 and the JAK-STAT pathway. Pharmacological and genetic NOTCH activation, but not inhibition, significantly suppressed AMKL cell proliferation in both in vitro and in vivo assays employing a patient-derived xenograft model. These results suggest that NOTCH inactivation underlies AMKL leukemogenesis. and NOTCH activation holds the potential for therapeutic application in AMKL.